Diabetes
Diabetes is a growing disease and an enormous global burden that is projected to affect more than 592 million people by 2035. AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes.
Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research program. AstraZeneca is committed to advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes.
Type 2 diabetes is a metabolic disorder characterised by chronically high levels of glucose in the blood. Find out more about the condition and its prevalence.
- Bydureon BCise (exenatide) – Great Britain Prescribing information
- Bydureon BCise (exenatide) – Northern Ireland Prescribing information
- Forxiga (dapagliflozin) Type 2 diabetes mellitus - Great Britain Prescribing Information
- Forxiga (dapagliflozin) Type 2 diabetes mellitus - Northern Ireland Prescribing Information
- Xigduo (dapagliflozin and metformin HCI) Prescribing Information
- ONGLYZA (saxagliptin) Prescribing Information
- QTERN (saxagliptin/ dapagliflozin) - Great Britain Prescribing Information
- QTERN (saxagliptin/ dapagliflozin) - Northern Ireland Prescribing Information
GB-37921 July 2022